semaglutide api manufacturing Newsletter: February 2026 – API GLP-1 Drug Manufacturing: Expansion &

Your physician can assess for contributing factors, review your overall treatment plan, and consider whether tirzepatide remains the most appropriate therapy for your situation

"As unsafe and unlawful mass compounding continues, the Wegovy penetration within the cash channel has been lower-than-expected," Novo Nordisk said in its Tuesday morning statement

According to the FDA's press release it agreed to approve the drug for obesity based on three randomised, double-blind, placebo-controlled trials during which more than 2,600 patients received Wegovy for up to 68 weeks and more than 1,500 patients received placebo (US FDA 2021)

Medical records

Success rates are modestmost regain weight within 2 years

Louis Aronne, an obesity medicine physician and director of the Comprehensive Weight Control Center at Weill Cornell Medicine and NewYork-Presbyterian, previously told TODAY.com